Cargando…

The right time to measure anti-Xa activity in critical illness: pharmacokinetics of therapeutic dose nadroparin

BACKGROUND: Peak anti-Xa activity of low-molecular-weight heparin nadroparin is measured 3 to 5 hours after subcutaneous injection. In critically ill patients, physiological changes and medical therapies may result in peak activities before or after this interval, possibly impacting dosing. OBJECTIV...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sytema, Jelmer G., Loef, Bert G., Loovers, Harriët M., Boer, Marijn, Touw, Daniël J., van Hulst, Marinus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10336191/ https://www.ncbi.nlm.nih.gov/pubmed/37449055 http://dx.doi.org/10.1016/j.rpth.2023.100185

Ejemplares similares

Effect of nadroparin on anti-Xa activity during nocturnal hemodialysis
por: Buitenwerf, Edward, et al.
Publicado: (2015)

Trough anti-Xa activity after intermediate dose nadroparin for thrombosis prophylaxis in critically ill patients with COVID-19 and acute kidney injury
por: Eck, R. J., et al.
Publicado: (2022)

Optimising the Nadroparin Dose for Thromboprophylaxis During Hemodialysis by Developing a Population Pharmacodynamic Model Using Anti-Xa Levels
por: Jaspers, Tessa C. C., et al.
Publicado: (2022)

Unintentional ingestion of a high dose of acenocoumarol in a young child
por: Brands, Martijn R, et al.
Publicado: (2021)

Bleeding complications of thromboprophylaxis with dabigatran, nadroparin or rivaroxaban for 6 weeks after total knee arthroplasty surgery: a randomised pilot study
por: van der Veen, Lucia, et al.
Publicado: (2021)

Population pharmacokinetics of nadroparin for thromboprophylaxis in COVID‐19 intensive care unit patients
por: Romano, Lorenzo G. R., et al.
Publicado: (2022)

The effect of renal impairment and obesity on anti-Xa peak and trough levels in patients receiving therapeutic doses of nadroparin: a comparison with control patients
por: Mast, L., et al.
Publicado: (2023)

Low and Highly Variable Exposure to Prophylactic LMWH Nadroparin in Critically Ill Patients: Back to the Drawing Board for Prophylactic Dosing?
por: Diepstraten, Jeroen, et al.
Publicado: (2022)

Population Pharmacokinetics and Probability of Target Attainment Analysis of Nadroparin in Different Stages of COVID-19
por: Piwowarczyk, Paweł, et al.
Publicado: (2023)

Efficacy and pharmacokinetics of intravenous paracetamol in the critically ill patient
por: Samson, AD, et al.
Publicado: (2009)

Direct treatment comparison of DAbigatran and RIvaroxaban versus NAdroparin in the prevention of venous thromboembolism after total knee arthroplasty surgery: design of a randomised pilot study (DARINA)
por: van Veen, Lucia, et al.
Publicado: (2013)

Tinzaparin vs. Nadroparin Safety and Efficacy in Neurosurgery
por: Wilhelmy, Florian, et al.
Publicado: (2021)

Nadroparine calcium or enoxaparine in acute coronary syndrome patients suffering renal insufficiency: The nadroparin versus enoxaparin (NaVe) study design
por: Gurfinkel, Enrique P, et al.
Publicado: (2004)

Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors
por: Persson, Pontus B
Publicado: (2015)

Anti-Xa Directed Thromboprophylaxis in Critically Ill Patients with Coronavirus Disease 2019
por: Mohamed, Adham, et al.
Publicado: (2022)

The Effect of Pregnancy and Inflammatory Bowel Disease on the Pharmacokinetics of Drugs Related to Inflammatory Bowel Disease—A Systematic Literature Review
por: Wiersma, Thomas K., et al.
Publicado: (2022)

Incidence, treatment and mortality of new-onset atrial fibrillation patients at the intensive care unit
por: Jacobs, Maartje S, et al.
Publicado: (2020)

Nadroparin calcium: Spontaneous retroperitoneal bleeding: 2 case reports
Publicado: (2022)

Use of anti-Xa factor titration as efficacy marker of enoxaparin in critically ill patients
por: Lage, S, et al.
Publicado: (2006)

Computer-assisted glucose control in critically ill patients
por: Vogelzang, Mathijs, et al.
Publicado: (2008)

Antitumor effects of nadroparin combined with radiotherapy in Lewis lung cancer models
por: Zhuang, Xibing, et al.
Publicado: (2018)

Effectiveness and Safety of Nadroparin Therapy in Preterm and Term Neonates with Venous Thromboembolism
por: Sol, Jeanine, et al.
Publicado: (2021)

Effects of dalteparin on anti‐Xa activities cannot be predicted in critically ill COVID‐19 patients
por: van der Heijden, Charlotte D. C. C., et al.
Publicado: (2022)

Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19
por: Hamilton, David Oliver, et al.
Publicado: (2021)

Effects of Routine Antithrombotic-Adjusted Dose of Rivaroxaban and Nadroparin Calcium on Tendon Healing of Rats: An Experimental Study
por: Altun, Suleyman, et al.
Publicado: (2021)

Rare complication of nadroparin injections: Skin necrosis and heparin‐induced thrombocytopenia syndrome
por: Malinauskiene, Laura, et al.
Publicado: (2022)

Sequential Therapy of Nadroparin and Rivaroxaban in the Initial Treatment of Patients With Acute Pulmonary Embolism
por: Xiong, Wei, et al.
Publicado: (2022)

An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients
por: Wallenburg, Eveline, et al.
Publicado: (2022)

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
por: Upreti, Vijay V, et al.
Publicado: (2013)

Correction to: An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients
por: Wallenburg, Eveline, et al.
Publicado: (2022)

Nadroparine-induced skin necrosis on a patient with essential thrombocythaemia: a case report
por: Pramateftakis, Manousos-Georgios, et al.
Publicado: (2009)

Fondaparınux Versus Nadroparın for Preventıon of Venous Thromboembolısm After Electıve Hıp and Knee Arthroplasty()
por: Argun, Mahmut, et al.
Publicado: (2013)

Preemptive dosage reduction of nadroparin in patients with renal failure: a retrospective case series
por: Russcher, Marije, et al.
Publicado: (2013)

Antifactor Xa Levels in Critically Ill Korean Patients Receiving Enoxaparin for Thromboprophylaxis: A Prospective Observational Study
por: Lim, So Yeon, et al.
Publicado: (2013)

Effect of critical illness on the pharmacokinetics and dose-response relationship of midazolam
por: Ovakim, D, et al.
Publicado: (2012)

Population Pharmacokinetics and Dose Optimization of Ganciclovir in Critically Ill Children
por: Li, SiChan, et al.
Publicado: (2021)

An experiment with VM/XA share
por: Pope, B G
Publicado: (1990)

Factor Xa inhibitors: critical considerations for clinical development and testing
por: Becker, Richard C.
Publicado: (2021)

Asymptomatic deep vein thrombosis in critically ill COVID-19 patients despite therapeutic levels of anti-Xa activity
por: Torres-Machorro, Adriana, et al.
Publicado: (2020)

Assessment of anti-factor Xa activity in critically ill COVID-19 patients receiving three different anticoagulation regimens
por: Hamad, Mohammed A, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9p1hqvojc2l09vvvjtfmh84eb4